Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

JHS Svendgaard Laboratories

NSEI:JHS
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
JHS
NSEI
₹482M
Market Cap
  1. Home
  2. IN
  3. Household
Company description

JHS Svendgaard Laboratories Limited, together with its subsidiaries, manufactures and sells a range of oral and dental products for adults and kids in India. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • JHS Svendgaard Laboratories has significant price volatility in the past 3 months.
JHS Share Price and Events
7 Day Returns
6.8%
NSEI:JHS
4.1%
IN Personal Products
-3.6%
IN Market
1 Year Returns
-70.8%
NSEI:JHS
-13.7%
IN Personal Products
-32.1%
IN Market
JHS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
JHS Svendgaard Laboratories (JHS) 6.8% -17.4% -49.5% -70.8% -81.3% -
IN Personal Products 4.1% -13.5% -16.7% -13.7% 7% 19%
IN Market -3.6% -26.9% -31.5% -32.1% -24.1% -15.2%
1 Year Return vs Industry and Market
  • JHS underperformed the Personal Products industry which returned -13.7% over the past year.
  • JHS underperformed the Market in India which returned -32.1% over the past year.
Price Volatility
JHS
Industry
5yr Volatility vs Market

Value

 Is JHS Svendgaard Laboratories undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for JHS Svendgaard Laboratories. This is due to cash flow or dividend data being unavailable. The share price is ₹7.85.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for JHS Svendgaard Laboratories's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are JHS Svendgaard Laboratories's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:JHS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in INR ₹-0.08
BSE:532771 Share Price ** BSE (2020-04-03) in INR ₹7.92
India Personal Products Industry PE Ratio Median Figure of 18 Publicly-Listed Personal Products Companies 19.97x
India Market PE Ratio Median Figure of 2,614 Publicly-Listed Companies 9.41x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of JHS Svendgaard Laboratories.

NSEI:JHS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:532771 Share Price ÷ EPS (both in INR)

= 7.92 ÷ -0.08

-103.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • JHS Svendgaard Laboratories is loss making, we can't compare its value to the IN Personal Products industry average.
  • JHS Svendgaard Laboratories is loss making, we can't compare the value of its earnings to the India market.
Price based on expected Growth
Does JHS Svendgaard Laboratories's expected growth come at a high price?
Raw Data
NSEI:JHS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -103.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
India Personal Products Industry PEG Ratio Median Figure of 5 Publicly-Listed Personal Products Companies 2.82x
India Market PEG Ratio Median Figure of 400 Publicly-Listed Companies 0.8x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for JHS Svendgaard Laboratories, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on JHS Svendgaard Laboratories's assets?
Raw Data
NSEI:JHS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in INR ₹26.84
BSE:532771 Share Price * BSE (2020-04-03) in INR ₹7.92
India Personal Products Industry PB Ratio Median Figure of 22 Publicly-Listed Personal Products Companies 1.56x
India Market PB Ratio Median Figure of 3,613 Publicly-Listed Companies 0.63x
NSEI:JHS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:532771 Share Price ÷ Book Value per Share (both in INR)

= 7.92 ÷ 26.84

0.3x

* Primary Listing of JHS Svendgaard Laboratories.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • JHS Svendgaard Laboratories is good value based on assets compared to the IN Personal Products industry average.
X
Value checks
We assess JHS Svendgaard Laboratories's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. JHS Svendgaard Laboratories has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is JHS Svendgaard Laboratories expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as JHS Svendgaard Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.5%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is JHS Svendgaard Laboratories expected to grow at an attractive rate?
  • Unable to compare JHS Svendgaard Laboratories's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare JHS Svendgaard Laboratories's earnings growth to the India market average as no estimate data is available.
  • Unable to compare JHS Svendgaard Laboratories's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NSEI:JHS Future Growth Rates Data Sources
Data Point Source Value (per year)
India Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 11.5%
India Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 9.6%
India Market Earnings Growth Rate Market Cap Weighted Average 19.2%
India Market Revenue Growth Rate Market Cap Weighted Average 8.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:JHS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:JHS Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
NSEI:JHS Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-12-31 1,356 -3
2019-09-30 1,383 -15
2019-06-30 1,294 -5
2019-03-31 1,270 -108 -7
2018-12-31 1,274 23
2018-09-30 1,318 40
2018-06-30 1,329 67
2018-03-31 1,409 138 261
2017-12-31 1,304 419
2017-09-30 1,093 411
2017-06-30 1,090 407
2017-03-31 1,051 -39 219

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if JHS Svendgaard Laboratories is high growth as no earnings estimate data is available.
  • Unable to determine if JHS Svendgaard Laboratories is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:JHS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from JHS Svendgaard Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:JHS Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
NSEI:JHS Past Financials Data
Date (Data in INR Millions) EPS *
2019-12-31 -0.08
2019-09-30
2019-06-30 -0.08
2019-03-31 -0.11
2018-12-31 0.27
2018-09-30
2018-06-30 1.18
2018-03-31 4.62
2017-12-31 8.04
2017-09-30 8.77
2017-06-30 9.35
2017-03-31 5.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if JHS Svendgaard Laboratories will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine JHS Svendgaard Laboratories's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. JHS Svendgaard Laboratories's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. JHS Svendgaard Laboratories's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess JHS Svendgaard Laboratories's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
JHS Svendgaard Laboratories has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has JHS Svendgaard Laboratories performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare JHS Svendgaard Laboratories's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • JHS Svendgaard Laboratories does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare JHS Svendgaard Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare JHS Svendgaard Laboratories's 1-year growth to the IN Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
JHS Svendgaard Laboratories's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from JHS Svendgaard Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:JHS Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1,355.88 -2.95 178.22
2019-09-30 1,382.53 -15.21 177.30
2019-06-30 1,294.36 -5.07 134.01
2019-03-31 1,269.74 -6.81 174.73
2018-12-31 1,273.70 22.96 162.93
2018-09-30 1,317.53 39.70 169.84
2018-06-30 1,329.21 66.72 135.40
2018-03-31 1,408.98 261.49 148.02
2017-12-31 1,304.30 418.86 113.00
2017-09-30 1,093.38 410.83 93.56
2017-06-30 1,089.75 406.80 92.46
2017-03-31 1,050.58 219.37 95.36
2016-12-31 1,030.94 -142.78 95.05
2016-09-30 1,059.16 -175.31 93.46
2016-06-30 1,006.57 -198.04 88.95
2016-03-31 1,000.85 -216.41 82.02
2015-12-31 959.04 -130.06 115.14
2015-09-30 834.72 -149.13 109.17
2015-06-30 696.18 -185.63 106.32
2015-03-31 553.24 -221.77 64.68
2014-12-31 417.69 -178.27 93.78
2014-09-30 362.74 -223.68 95.78
2014-06-30 330.02 -270.32 107.03
2014-03-31 352.80 -288.10 129.36
2013-12-31 468.30 -175.53 146.06
2013-09-30 505.67 -145.37 152.73
2013-06-30 550.42 -152.46 111.72

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if JHS Svendgaard Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • JHS Svendgaard Laboratories used its assets less efficiently than the IN Personal Products industry average last year based on Return on Assets.
  • It is difficult to establish if JHS Svendgaard Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess JHS Svendgaard Laboratories's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
JHS Svendgaard Laboratories has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is JHS Svendgaard Laboratories's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up JHS Svendgaard Laboratories's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • JHS Svendgaard Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • JHS Svendgaard Laboratories's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of JHS Svendgaard Laboratories's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 17.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from JHS Svendgaard Laboratories Company Filings, last reported 3 months ago.

NSEI:JHS Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31
2019-09-30
2019-06-30 1,806.38 58.11 56.97
2019-03-31 1,806.38 87.33 56.93
2018-12-31 1,750.31 56.31 159.43
2018-09-30 1,750.31 56.31 159.43
2018-06-30 1,741.65 11.05 363.93
2018-03-31 1,741.65 30.99 243.38
2017-12-31 1,689.41 10.79 360.66
2017-09-30 1,689.41 10.79 360.66
2017-06-30 1,343.70 22.23 68.60
2017-03-31 1,343.71 25.21 67.38
2016-12-31 1,040.84 15.52 94.75
2016-09-30 1,040.84 15.52 94.75
2016-06-30 1,005.86 26.03 28.82
2016-03-31 1,005.86 26.03 28.82
2015-12-31 1,181.11 212.59 16.71
2015-09-30 1,181.11 212.59 16.71
2015-06-30 1,195.99 331.72 9.75
2015-03-31 1,195.99 331.72 9.75
2014-12-31
2014-09-30 528.32 434.37 14.62
2014-06-30
2014-03-31 619.14 995.53 23.55
2013-12-31 730.65 689.82 30.87
2013-09-30 730.65 689.82 30.87
2013-06-30 892.20 759.00 8.05
  • JHS Svendgaard Laboratories's level of debt (3.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (124.4% vs 3.2% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on JHS Svendgaard Laboratories's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess JHS Svendgaard Laboratories's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. JHS Svendgaard Laboratories has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is JHS Svendgaard Laboratories's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from JHS Svendgaard Laboratories dividends.
If you bought ₹2,000 of JHS Svendgaard Laboratories shares you are expected to receive ₹0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate JHS Svendgaard Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate JHS Svendgaard Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:JHS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
India Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.5%
India Market Average Dividend Yield Market Cap Weighted Average of 1418 Stocks 2%
India Minimum Threshold Dividend Yield 10th Percentile 0.4%
India Bottom 25% Dividend Yield 25th Percentile 1%
India Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:JHS Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
NSEI:JHS Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2013-02-11 0.000 0.000
2012-11-06 0.000 0.000
2012-08-21 0.000 0.000
2012-08-17 0.000 0.000
2012-06-14 0.000 0.000
2012-01-02 0.750 2.004
2010-05-31 0.500 0.845
2009-08-25 0.250 0.551
2009-07-01 0.250 1.071

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as JHS Svendgaard Laboratories has not reported any payouts.
  • Unable to verify if JHS Svendgaard Laboratories's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of JHS Svendgaard Laboratories's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as JHS Svendgaard Laboratories has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess JHS Svendgaard Laboratories's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can JHS Svendgaard Laboratories afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. JHS Svendgaard Laboratories has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of JHS Svendgaard Laboratories's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paramvir Pabla
COMPENSATION ₹2,575,920
TENURE AS CEO 5.9 years
CEO Bio

Mr. Paramvir Singh Pabla serves as Chief Executive Officer of JHS Svendgaard Laboratories Ltd. since May 30, 2014.

CEO Compensation
  • Paramvir's compensation has increased whilst company is loss making.
  • Paramvir's remuneration is about average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the JHS Svendgaard Laboratories management team in years:

5.9
Average Tenure
46
Average Age
  • The average tenure for the JHS Svendgaard Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Paramvir Pabla

TITLE
Chief Executive Officer
COMPENSATION
₹3M
TENURE
5.9 yrs

Nikhil Nanda

TITLE
MD & Executive Director
COMPENSATION
₹6M
AGE
47

Ashish Goel

TITLE
Chief Financial Officer
COMPENSATION
₹4M
AGE
34
TENURE
1.7 yrs

Rakesh Sabharwal

TITLE
General Manager of Accounts

Chetan Batra

TITLE
Company Secretary & Compliance Officer
AGE
32
TENURE
0.8 yrs

R. Dogra

TITLE
Head of Unit-III
AGE
54
TENURE
16.3 yrs

Ajay Jha

TITLE
Head of Unit - I
AGE
46
TENURE
14.6 yrs
Board of Directors Tenure

Average tenure and age of the JHS Svendgaard Laboratories board of directors in years:

4.2
Average Tenure
53
Average Age
  • The tenure for the JHS Svendgaard Laboratories board of directors is about average.
Board of Directors

Vanamali Polavaram

TITLE
Non-Executive Non-Independent Chairman
COMPENSATION
₹120K
AGE
73
TENURE
5.2 yrs

Nikhil Nanda

TITLE
MD & Executive Director
COMPENSATION
₹6M
AGE
47

Mukul Pathak

TITLE
Non Executive Non-Independent Director
COMPENSATION
₹220K
AGE
52
TENURE
4.8 yrs

Nikhil Vora

TITLE
Nominee Director
AGE
47
TENURE
4.2 yrs

Rohina Sangtani

TITLE
Non Executive Non-Independent Woman Director
COMPENSATION
₹120K
AGE
54
TENURE
2.4 yrs

Balbir Verma

TITLE
Additional Independent Director
COMPENSATION
₹90K
AGE
63
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess JHS Svendgaard Laboratories's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. JHS Svendgaard Laboratories has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did You Miss JHS Svendgaard Laboratories's (NSE:JHS) 87% Share Price Gain?

View our latest analysis for JHS Svendgaard Laboratories Because JHS Svendgaard Laboratories is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Simply Wall St -

Can We See Significant Insider Ownership On The JHS Svendgaard Laboratories Limited (NSE:JHS) Share Register?

See our latest analysis for JHS Svendgaard Laboratories NSEI:JHS Ownership Summary, July 5th 2019 What Does The Lack Of Institutional Ownership Tell Us About JHS Svendgaard Laboratories? … Insider Ownership Of JHS Svendgaard Laboratories While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. … Private Company Ownership We can see that Private Companies own 3.5%, of the shares on issue.

Simply Wall St -

Do Institutions Own JHS Svendgaard Laboratories Limited (NSE:JHS) Shares?

Every investor in JHS Svendgaard Laboratories Limited (NSE:JHS) should be aware of the most powerful shareholder groups. … JHS Svendgaard Laboratories is not a large company by global standards. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Why We’re Not Keen On JHS Svendgaard Laboratories Limited’s (NSE:JHS) 0.06% Return On Capital

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … What is Return On Capital Employed (ROCE)? … ROCE measures the 'return' (pre-tax profit) a company generates from capital employed in its business.

Simply Wall St -

Read This Before Judging JHS Svendgaard Laboratories Limited's (NSE:JHS) ROE

We'll use ROE to examine JHS Svendgaard Laboratories Limited (NSE:JHS), by way of a worked example. … See our latest analysis for JHS Svendgaard Laboratories? … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

What Kind Of Shareholder Appears On The JHS Svendgaard Laboratories Limited's (NSE:JHS) Shareholder Register?

Every investor in JHS Svendgaard Laboratories Limited (NSE:JHS) should be aware of the most powerful shareholder groups. … JHS Svendgaard Laboratories is not a large company by global standards. … See our latest analysis for JHS Svendgaard Laboratories

Simply Wall St -

What You Must Know About JHS Svendgaard Laboratories Limited's (NSE:JHS) Return on Equity

and looking to gauge the potential return on investment in JHS Svendgaard Laboratories Limited (NSE:JHS). … JHS Svendgaard Laboratories Limited (NSE:JHS) generated a below-average return on equity of 14.96% in the past 12 months, while its industry returned 26.03%. … An investor may attribute an inferior ROE to a relatively inefficient performance, and whilst this can often be the case, knowing the nuts and bolts of the ROE calculation may change that perspective and give you a deeper insight into JHS's past performance.

Simply Wall St -

Company Info

Description

JHS Svendgaard Laboratories Limited, together with its subsidiaries, manufactures and sells a range of oral and dental products for adults and kids in India. The company offers oral care products, such as toothbrushes, toothpastes, mouthwash products, hand sanitizers, laundry detergents, room fresheners, and denture products under the Dr. Gold and Aquawhite brands. It also provides contract manufacturing services for oral care products of other brands; and operates a chain of dental clinics, as well as is involved in retail trade in stores. The company also sells its products through its Website, aquawhite.in. It also exports its products. JHS Svendgaard Laboratories Limited was founded in 1997 and is headquartered in New Delhi, India.

Details
Name: JHS Svendgaard Laboratories Limited
JHS
Exchange: NSEI
Founded: 1997
₹482,331,682
60,900,465
Website: http://www.svendgaard.com
Address: JHS Svendgaard Laboratories Limited
B-1/E-23, Mohan Co-operative Industrial Estate,
Mathura Road,
New Delhi,
Delhi, 110044,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 532771 Equity Shares Mumbai Stock Exchange IN INR 21. Oct 2006
NSEI JHS Equity Shares National Stock Exchange of India IN INR 21. Oct 2006
Number of employees
Current staff
Staff numbers
0
JHS Svendgaard Laboratories employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 13:58
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2018/05/17
Last earnings filing: 2020/02/11
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.